{"id":67784,"date":"2026-06-09T22:41:11","date_gmt":"2026-06-09T14:41:11","guid":{"rendered":"https:\/\/flcube.com\/?p=67784"},"modified":"2026-06-09T22:41:13","modified_gmt":"2026-06-09T14:41:13","slug":"zai-lab-secures-nmpa-approval-for-tivdak-tisotumab-vedotin-in-recurrent-or-metastatic-cervical-cancer-based-on-phase-iii-innovatv-301-data","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67784","title":{"rendered":"Zai Lab Secures NMPA Approval for Tivdak (Tisotumab Vedotin) in Recurrent or Metastatic Cervical Cancer Based on Phase III innovaTV 301 Data"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Zai Lab<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ZLAB:NASDAQ\">NASDAQ: ZLAB<\/a>; <a href=\"https:\/\/www.google.com\/finance\/quote\/9688:HKG\">HKG: 9688<\/a>) announced today that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has approved the <strong>Biologics License Application (BLA)<\/strong> for <strong>Tivdak<\/strong> (tisotumab vedotin injection) for the treatment of adult patients with recurrent or metastatic cervical cancer whose disease has progressed on or after chemotherapy.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Name<\/strong><\/td><td>Tivdak (tisotumab vedotin injection)<\/td><\/tr><tr><td><strong>Marketing Authorization Holder<\/strong><\/td><td>Zai Lab (NASDAQ: ZLAB; HKG: 9688)<\/td><\/tr><tr><td><strong>Approval Authority<\/strong><\/td><td>National Medical Products Administration (NMPA), China<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Recurrent or metastatic cervical cancer post-chemotherapy progression<\/td><\/tr><tr><td><strong>Technology Origin<\/strong><\/td><td>Antibody-drug conjugate (ADC) combining Genmab&#8217;s TF-targeted monoclonal antibody with Pfizer&#8217;s ADC technology<\/td><\/tr><tr><td><strong>Global Approvals<\/strong><\/td><td>Previously approved in US, Japan, EU, UK, Macau (China), and Hong Kong (China)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-clinical-trial-results-innovatv-301-study\" class=\"wp-block-heading\">Clinical Trial Results \u2013 innovaTV 301 Study<\/h2>\n\n\n\n<h3 id=\"h-study-design-amp-population\" class=\"wp-block-heading\">Study Design &amp; Population<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Type<\/strong><\/td><td>Global, randomized, controlled Phase III<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Overall survival (OS)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Adult patients with previously treated recurrent or metastatic cervical cancer<\/td><\/tr><tr><td><strong>Comparator<\/strong><\/td><td>Chemotherapy<\/td><\/tr><tr><td><strong>Chinese Subgroup<\/strong><\/td><td>Included in exploratory analysis with positive results<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 id=\"h-key-efficacy-findings\" class=\"wp-block-heading\">Key Efficacy Findings<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Primary Endpoint Met<\/strong>: Demonstrated statistically significant overall survival benefit versus chemotherapy<\/li>\n\n\n\n<li><strong>Chinese Subgroup Analysis<\/strong>: Consistent efficacy observed in Chinese patient population<\/li>\n\n\n\n<li><strong>Clinical Significance<\/strong>: Addresses critical unmet need in second-line cervical cancer treatment<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-disease-context-amp-market-opportunity\" class=\"wp-block-heading\">Disease Context &amp; Market Opportunity<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cervical Cancer Burden<\/strong>: China accounts for approximately 18% of global cervical cancer cases annually<\/li>\n\n\n\n<li><strong>Treatment Landscape<\/strong>: Limited effective options for patients progressing after first-line platinum-based chemotherapy<\/li>\n\n\n\n<li><strong>ADC Innovation<\/strong>: Represents advancement in targeted therapy for gynecological malignancies<\/li>\n\n\n\n<li><strong>Tissue Factor Targeting<\/strong>: Novel mechanism leveraging TF overexpression in cervical cancer cells<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Commercial Launch<\/strong>: Positions Zai Lab to address significant unmet need in China&#8217;s cervical cancer market<\/li>\n\n\n\n<li><strong>Partnership Model<\/strong>: Leverages established collaboration between Zai Lab, Genmab, and Pfizer<\/li>\n\n\n\n<li><strong>Integrated Portfolio<\/strong>: Complements Zai Lab&#8217;s existing oncology pipeline and commercial infrastructure<\/li>\n\n\n\n<li><strong>Global Harmonization<\/strong>: Aligns Chinese approval with international regulatory decisions<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-forward-looking-statements\" class=\"wp-block-heading\">Forward-Looking Statements<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This brief contains forward-looking statements regarding regulatory approvals, clinical development, market opportunities, and commercial expectations. Actual results may differ due to risks including market adoption, competitive dynamics, reimbursement challenges, and post-marketing safety surveillance requirements.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zai Lab (NASDAQ: ZLAB; HKG: 9688) announced today that China&#8217;s National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,869,868,15,413],"class_list":["post-67784","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-hkg-9688","tag-nasdaq-zlab","tag-product-approvals","tag-zai-lab"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zai Lab Secures NMPA Approval for Tivdak (Tisotumab Vedotin) in Recurrent or Metastatic Cervical Cancer Based on Phase III innovaTV 301 Data - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Zai Lab (NASDAQ: ZLAB; HKG: 9688) announced today that China&#039;s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for Tivdak (tisotumab vedotin injection) for the treatment of adult patients with recurrent or metastatic cervical cancer whose disease has progressed on or after chemotherapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67784\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zai Lab Secures NMPA Approval for Tivdak (Tisotumab Vedotin) in Recurrent or Metastatic Cervical Cancer Based on Phase III innovaTV 301 Data\" \/>\n<meta property=\"og:description\" content=\"Zai Lab (NASDAQ: ZLAB; HKG: 9688) announced today that China&#039;s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for Tivdak (tisotumab vedotin injection) for the treatment of adult patients with recurrent or metastatic cervical cancer whose disease has progressed on or after chemotherapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67784\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-09T14:41:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-09T14:41:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67784#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67784\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zai Lab Secures NMPA Approval for Tivdak (Tisotumab Vedotin) in Recurrent or Metastatic Cervical Cancer Based on Phase III innovaTV 301 Data\",\"datePublished\":\"2026-06-09T14:41:11+00:00\",\"dateModified\":\"2026-06-09T14:41:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67784\"},\"wordCount\":356,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"HKG: 9688\",\"NASDAQ: ZLAB\",\"Product approvals\",\"Zai Lab\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67784#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67784\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67784\",\"name\":\"Zai Lab Secures NMPA Approval for Tivdak (Tisotumab Vedotin) in Recurrent or Metastatic Cervical Cancer Based on Phase III innovaTV 301 Data - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-09T14:41:11+00:00\",\"dateModified\":\"2026-06-09T14:41:13+00:00\",\"description\":\"Zai Lab (NASDAQ: ZLAB; HKG: 9688) announced today that China's National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for Tivdak (tisotumab vedotin injection) for the treatment of adult patients with recurrent or metastatic cervical cancer whose disease has progressed on or after chemotherapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67784#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67784\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67784#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zai Lab Secures NMPA Approval for Tivdak (Tisotumab Vedotin) in Recurrent or Metastatic Cervical Cancer Based on Phase III innovaTV 301 Data\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zai Lab Secures NMPA Approval for Tivdak (Tisotumab Vedotin) in Recurrent or Metastatic Cervical Cancer Based on Phase III innovaTV 301 Data - Insight, China&#039;s Pharmaceutical Industry","description":"Zai Lab (NASDAQ: ZLAB; HKG: 9688) announced today that China's National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for Tivdak (tisotumab vedotin injection) for the treatment of adult patients with recurrent or metastatic cervical cancer whose disease has progressed on or after chemotherapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67784","og_locale":"en_US","og_type":"article","og_title":"Zai Lab Secures NMPA Approval for Tivdak (Tisotumab Vedotin) in Recurrent or Metastatic Cervical Cancer Based on Phase III innovaTV 301 Data","og_description":"Zai Lab (NASDAQ: ZLAB; HKG: 9688) announced today that China's National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for Tivdak (tisotumab vedotin injection) for the treatment of adult patients with recurrent or metastatic cervical cancer whose disease has progressed on or after chemotherapy.","og_url":"https:\/\/flcube.com\/?p=67784","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-09T14:41:11+00:00","article_modified_time":"2026-06-09T14:41:13+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67784#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67784"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zai Lab Secures NMPA Approval for Tivdak (Tisotumab Vedotin) in Recurrent or Metastatic Cervical Cancer Based on Phase III innovaTV 301 Data","datePublished":"2026-06-09T14:41:11+00:00","dateModified":"2026-06-09T14:41:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67784"},"wordCount":356,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","HKG: 9688","NASDAQ: ZLAB","Product approvals","Zai Lab"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67784#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67784","url":"https:\/\/flcube.com\/?p=67784","name":"Zai Lab Secures NMPA Approval for Tivdak (Tisotumab Vedotin) in Recurrent or Metastatic Cervical Cancer Based on Phase III innovaTV 301 Data - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-09T14:41:11+00:00","dateModified":"2026-06-09T14:41:13+00:00","description":"Zai Lab (NASDAQ: ZLAB; HKG: 9688) announced today that China's National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for Tivdak (tisotumab vedotin injection) for the treatment of adult patients with recurrent or metastatic cervical cancer whose disease has progressed on or after chemotherapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67784#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67784"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67784#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zai Lab Secures NMPA Approval for Tivdak (Tisotumab Vedotin) in Recurrent or Metastatic Cervical Cancer Based on Phase III innovaTV 301 Data"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67784","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67784"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67784\/revisions"}],"predecessor-version":[{"id":67785,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67784\/revisions\/67785"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67784"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67784"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67784"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}